🔗 Share this article Users Stopping Weight-Loss Injections Put On Pounds Four Times Faster Than Those on Conventional Diets Obesity treatment often requires ongoing approaches. Fresh analysis indicates that people who come off blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional lifestyle plans. Research printed in a major medical journal demonstrates that while obese people can lose about a fifth of their body weight while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month after stopping. "Users using such treatments should be aware of the danger of quick rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb. That rate of recovery suggests a return to pre-treatment weight in about 18 months. Analyzing Therapies The analysis, which examined 37 of studies involving thousands of patients, contrasted the results of the injectable medications with older methods. Researchers point out that individuals who lose weight through lifestyle changes alone generally experience a more gradual creep back—approximately 0.1 kg a month—after stopping. The Reason for the Rapid Regain Doctors propose the mode of action of the jabs explains the amplified weight return. These medications copy a body's own chemical called GLP-1, which moderates feelings of fullness. "Long-term administration of GLP-1 concentrations far above than normal might result in the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert. "Discontinuation of this hormone supplement results in appetite is no longer kept in check, making binge eating far more likely." A Chronic Issue? Health authorities advise the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications. Professionals argue that, considering the high risk of relapse, the treatment should be considered life-long. This view is supported by drug manufacturers, who say that the findings "underscore the persistent character of obesity," akin to managing diseases like high blood pressure. User Accounts Individuals who have come off the medication explain a intense resurgence of appetite. "I experienced a switch that goes on and you become ravenous," described one woman. This challenge is compounded if individuals have not developed lasting lifestyle or habit modifications during treatment. Significant Interest Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high. Use is more common among women than men. The 40s and 50s age group shows the highest level of interest. A large proportion obtain the medications through private prescriptions rather than public health services. Finally, experts caution that while GLP-1 drugs are effective agents for shedding pounds, they are not a magic solution and long-term success hinges on integrated behavioural support.
Obesity treatment often requires ongoing approaches. Fresh analysis indicates that people who come off blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional lifestyle plans. Research printed in a major medical journal demonstrates that while obese people can lose about a fifth of their body weight while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month after stopping. "Users using such treatments should be aware of the danger of quick rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb. That rate of recovery suggests a return to pre-treatment weight in about 18 months. Analyzing Therapies The analysis, which examined 37 of studies involving thousands of patients, contrasted the results of the injectable medications with older methods. Researchers point out that individuals who lose weight through lifestyle changes alone generally experience a more gradual creep back—approximately 0.1 kg a month—after stopping. The Reason for the Rapid Regain Doctors propose the mode of action of the jabs explains the amplified weight return. These medications copy a body's own chemical called GLP-1, which moderates feelings of fullness. "Long-term administration of GLP-1 concentrations far above than normal might result in the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert. "Discontinuation of this hormone supplement results in appetite is no longer kept in check, making binge eating far more likely." A Chronic Issue? Health authorities advise the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications. Professionals argue that, considering the high risk of relapse, the treatment should be considered life-long. This view is supported by drug manufacturers, who say that the findings "underscore the persistent character of obesity," akin to managing diseases like high blood pressure. User Accounts Individuals who have come off the medication explain a intense resurgence of appetite. "I experienced a switch that goes on and you become ravenous," described one woman. This challenge is compounded if individuals have not developed lasting lifestyle or habit modifications during treatment. Significant Interest Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high. Use is more common among women than men. The 40s and 50s age group shows the highest level of interest. A large proportion obtain the medications through private prescriptions rather than public health services. Finally, experts caution that while GLP-1 drugs are effective agents for shedding pounds, they are not a magic solution and long-term success hinges on integrated behavioural support.